New Findings Reveal Some BRCA2 Variants Linked to Moderate, Not High, Breast Cancer Risk

| November 19, 2026
Scientifically reviewed by Priya Malhotra, PhD; and Elizabeth Kass, MD, PhD

The study, which involved Breast Cancer Research Foundation investigators, found that the new variants conferred a lower risk than previously described BRCA2 mutations

Key Takeaways

  • Researchers at the Mayo Clinic identified a new group of BRCA2 gene variants that are associated with moderate breast cancer risk.
  • The study involved Breast Cancer Research Foundation investigators, including Dr. Fergus Couch, the last author on the publication.
  • These variants, known as reduced penetrance pathogenic variants (RPPVs), only partly disrupt the BRCA2 protein’s ability to repair damaged DNA. As a result, they raise breast cancer risk less than the more familiar harmful BRCA2 variants.
  • The study’s findings can help lead to personalized treatments for patients with different BRCA2 gene mutations, as not all of them carry the same level of risk.

Researchers recently identified a group of BCRA2 gene variants associated with moderate breast cancer risk. The study, published in Nature Communications, involved Breast Cancer Research Foundation (BCRF) investigators Drs. Fergus Couch (the last author on the publication), Katherine Nathanson, Tuya Pal, and Susan Domchek.

When BCRA2 genes mutate, they can increase a person’s risk of breast and other cancers. Only 5-10% of cancers are hereditary, but women with a BCRA2 gene mutation have a 45-69% lifetime risk of developing breast cancer as opposed to 12% of the general population. There are many different BCRA2 mutations, which scientists continue to uncover: In 2025, a study led by BCRF-funded investigator Dr. Couch clarified the risk associated with 7,000 BCRA2 variants that previously had uncertain significance.

In this study, the team investigated 70 BRCA2 variants labeled as hypomorphic because they only partially disrupt BRCA2 function. The variants were divided into 34 “strong” hypomorphs—those with greater effects on function—and 36 “weak” hypomorphs.

Researchers discovered that the strong hypomorphs were associated with a moderate risk of developing breast cancer, about two to two-and-a-half times higher than noncarriers, and an estimated lifetime risk of more than 20%. By comparison, those with pathogenic variants (PVs) of BCRA2 have an up to 70% lifetime risk of breast cancer. The authors emphasized that carriers of BCRA2 RPPVs may still qualify for high-risk breast cancer screenings.

The BRCA2 gene normally helps cells accurately repair a dangerous type of DNA damage in which both strands of the DNA are broken, through a process called homologous recombination.When both copies of the gene do not function, cells develophomologous recombination deficiency (HRD) and must rely on backup repair methods that are more error-prone. Drugs called PARP inhibitors block one of these backup routes, leaving cancer cells with HRD unable to fix their DNA, which causes them to die. This is why tumors with HRD tend to respond to PARP inhibitors. The study found that only 32% of tumors with hypomorphic variants displayed HRD as opposed to 83% of tumors with classic harmful BRCA2 variants and 7% with harmless variants. In laboratory studies, they found that among strong hypomorphs 97% (31 out of 32) made cells significantly sensitive to the PARP inhibitor olaparib. This suggests that some patients with these variants could benefit from PARP inhibitors, but because most of their tumors don’t show HRD, whether patients’ tumors would respond the same way remains to be seen.

These findings increase our understanding of how hypomorphic variants impact breast cancer risk and suggest that not all BRCA2 mutations carry the same level of risk. Further studies are needed, but results stand to help personalize risk assessment and prevention strategies, potentially helping some avoid or delay unnecessary risk-reducing (preventative) surgeries.

The team cautioned that the 70 hypomorphic variants studied may not fully “represent the behavior” of all possible hypomorphic variants, and that larger studies and the use of other evidence is needed to assess these variants. The study, however, represents an important step towards more precise risk assessment and better care.

legacy-Society

Support research with a legacy gift. Sample, non-binding bequest language:

I give to the Breast Cancer Research Foundation, located in New York, NY, federal tax identification number 13-3727250, ________% of my total estate (or $_____).

Learn More
Donate